Sign in Subscribe
Cancer research

Breakthrough in Colon Cancer Research Reveals Macrophage's Role in Immunotherapy Resistance

Strategic Insights

— 1 min read

Scientists at Rizhao People's Hospital in Shandong, People's Republic of China, have made a significant discovery in the field of colon cancer research. Through single-cell RNA sequencing analysis, they identified macrophages as a dominant immune subset that interacts with NK cells and fibroblasts, promoting immunosuppression. This research has shed new light on the complex tumor microenvironment that contributes to immunotherapy resistance.

Key Takeaways:

  • Researchers identified macrophages as a dominant immune subset (16% of TME) that interacts with NK cells and fibroblasts via HLA-CD8A and COL1A1/2-CD44 signaling, promoting immunosuppression.
  • A 10-gene macrophage-related prognostic signature (including BCAP31, PKM, and IFNGR1) was developed that effectively stratified patients into high- and low-risk groups, with high-risk cases exhibiting enriched M0/M2 macrophages, Treg infiltration, and resistance to immunotherapy.
  • Functional validation revealed that BCAP31 promotes CRC cell invasion and migration, while IFNGR1 demonstrated a protective role supported by Mendelian randomization (OR = 0.72).
  • BCAP31 was identified as a key risk gene that promotes CRC metastasis via oxidative phosphorylation-dependent macrophage immunosuppression.
  • Researchers proposed BCAP31 as a potential therapeutic target for colon cancer treatment.
  • The study highlights the critical role of macrophage-driven immune dysregulation in CRC progression and offers new insights into mitochondrial-immune crosstalk in the TME.

Statistics:

  • 16% of the tumor microenvironment (TME) consists of macrophages, which interact with NK cells and fibroblasts via specific signaling pathways.
  • The ratio of M0/M2 macrophages in high-risk cases was statistically significant (p = 2.5e-06).
  • BCAP31 was identified as a key risk gene that promotes CRC metastasis, with an odds ratio (OR) of 1.72.

Sources:

  • NewsRx: Investigators at Rizhao People's Hospital Release New Data on Colon Cancer (BCAP31 Promotes Colorectal Cancer Metastasis via Oxidative Phosphorylation-Dependent Macrophage Immunosuppression: A Single-Cell Transcriptomic Study).
  • Cancer Weekly: Investigators at Rizhao People's Hospital Release New Data on Colon Cancer (BCAP31 Promotes Colorectal Cancer Metastasis via Oxidative Phosphorylation-Dependent Macrophage Immunosuppression: A Single-Cell Transcriptomic Study).
  • Free Radical Biology and Medicine: BCAP31 Promotes Colorectal Cancer Metastasis via Oxidative Phosphorylation-Dependent Macrophage Immunosuppression: A Single-Cell Transcriptomic Study (2025).

Read more